Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo‐Controlled Phase 3 Trial
Anita H. Clayton, Robert Lasser, Sagar V. Parikh, et al.
American Journal of Psychiatry (2023) Vol. 180, Iss. 9, pp. 676-684
Closed Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Zuranolone for the Treatment of Postpartum Depression
Kristina M. Deligiannidis, Samantha Meltzer‐Brody, Bassem Maximos, et al.
American Journal of Psychiatry (2023) Vol. 180, Iss. 9, pp. 668-675
Closed Access | Times Cited: 98
Understanding the mechanism of action and clinical effects of neuroactive steroids and GABAergic compounds in major depressive disorder
Andrew J. Cutler, Gregory W. Mattingly, Vladimir Maletic
Translational Psychiatry (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 60
Modulators of GABAA receptor-mediated inhibition in the treatment of neuropsychiatric disorders: past, present, and future
Scott M. Thompson
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 83-95
Closed Access | Times Cited: 29
Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances
Ana Salomé Correia, Nuno Vale
International Journal of Translational Medicine (2024) Vol. 4, Iss. 1, pp. 176-196
Open Access | Times Cited: 8
Novel insight into astrocyte-mediated gliotransmission modulates the synaptic plasticity in major depressive disorder
Lan Lei, Yufei Wang, Cong-Ya Chen, et al.
Life Sciences (2024) Vol. 355, pp. 122988-122988
Closed Access | Times Cited: 7
A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Yi‐Ru Bai, Dong‐Jie Seng, Ying Xu, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116706-116706
Closed Access | Times Cited: 6
Zuranolone – synthetic neurosteroid in treatment of mental disorders: narrative review
Rafał Marecki, Joanna Kałuska, Agata Kolanek, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 13
The magnitude and sustainability of treatment benefit of zuranolone on function and well-being as assessed by the SF-36 in adult patients with MDD and PPD: An integrated analysis of 4 randomized clinical trials
Anita H. Clayton, Ellison Suthoff, Rakesh K. Jain, et al.
Journal of Affective Disorders (2024) Vol. 351, pp. 904-914
Open Access | Times Cited: 5
Opportunities for use of neuroimaging in de-risking drug development and improving clinical outcomes in psychiatry: an industry perspective
Amit Etkin, Jessica Powell, Adam Savitz
Neuropsychopharmacology (2024) Vol. 50, Iss. 1, pp. 258-268
Open Access | Times Cited: 5
Zuranolone Concentrations in the Breast Milk of Healthy, Lactating Individuals
Kristina M. Deligiannidis, Amy Bullock, Indrani Nandy, et al.
Journal of Clinical Psychopharmacology (2024)
Open Access | Times Cited: 4
Antidepressants and Weight Gain: An Update on the Evidence and Clinical Implications
Lauren Moss, Marci Laudenslager, Kristine J. Steffen, et al.
Current Obesity Reports (2025) Vol. 14, Iss. 1
Closed Access
Design, Synthesis, and Pharmacological Evaluation of Nonsteroidal Tricyclic Ligands as Modulators of GABAA Receptors
Yue Xu, Martin Mortensen, Seth Liebowitz, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Clinical Utility of Zuranolone for Postpartum Depression: A Narrative Review
Athanasia Giannopoulos, Joshna Singh, Kristina M. Deligiannidis
Neuropsychiatric Disease and Treatment (2025) Vol. Volume 21, pp. 93-105
Open Access
Emerging Medications for Treatment-Resistant Depression: A Review with Perspective on Mechanisms and Challenges
Michael J. Lucido, Boadie W. Dunlop
Brain Sciences (2025) Vol. 15, Iss. 2, pp. 161-161
Open Access
Pharmacotherapy of postpartum depression: An update
Keshav Kumar, Kumari Pallavi, Kumar Martand, et al.
Indian Journal of Obstetrics and Gynecology Research (2025) Vol. 12, Iss. 1, pp. 1-9
Open Access
FDA‐Approved Zuranolone: First Oral Treatment for Postpartum Depression, Ushering in a New Era of Hope; A Narrative Review
Muhammad Haris, Sameen Mukhtar, Mubashir Mohiuddin, et al.
Health Science Reports (2025) Vol. 8, Iss. 3
Open Access
Age-related abnormalities in brain functional and molecular neuroimaging signatures in first-episode depression
Yu Jiang, Yuan Chen, Ruiping Zheng, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025) Vol. 138, pp. 111330-111330
Closed Access
A narrative review of the placebo effect: historical roots, current applications, and emerging insights
Cagri Ozpolat, Yagmur Okcay, Kemal Gökhan Ulusoy, et al.
European Journal of Clinical Pharmacology (2025)
Closed Access
Rapid-Acting Treatments for Perinatal Depression: Clinical Landscapes and Future Horizons
Emily Beydler, Amanda Koire, Elizabeth R. Steuber, et al.
International Journal of Environmental Research and Public Health (2025) Vol. 22, Iss. 4, pp. 546-546
Open Access
Comment on the study “the efficacy and safety of zuranolone for treatment of depression: a systematic review and meta-analysis”
Mohammad Umer, Zaofasha Zaheer, Aiman Naveed
Psychopharmacology (2025)
Closed Access
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Courtney M. Vecera, Alan C. Courtes, Gregory Jones, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1572-1572
Open Access | Times Cited: 12
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study
Sagar V. Parikh, Scott T. Aaronson, Sanjay J. Mathew, et al.
Neuropsychopharmacology (2023) Vol. 49, Iss. 2, pp. 467-475
Open Access | Times Cited: 11
Zuranolone: First Approval
Young‐A Heo
Drugs (2023) Vol. 83, Iss. 16, pp. 1559-1567
Closed Access | Times Cited: 11
The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis
Mackenzie Winslow, Emily White, Suzanne J. Rose, et al.
International Journal of Clinical Pharmacy (2024) Vol. 46, Iss. 3, pp. 590-601
Closed Access | Times Cited: 4
Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses
Yu‐Wei Lin, Yu‐Kang Tu, Kuo‐Chuan Hung, et al.
EClinicalMedicine (2023) Vol. 66, pp. 102308-102308
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top